NCT03891953View on ClinicalTrials.gov

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Carcinoma, Non-Small-Cell LungMelanomaNasopharyngeal CarcinomaMicrosatellite Stable Colorectal CancerTriple Negative Breast Cancer
Interventions
DRUG

DKY709

Novel immunomodulatory agent

DRUG

PDR001

PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2

Trial Locations (9)

10002

Novartis Investigative Site, Taipei

37203

Sarah Cannon Research Institute, Nashville

45147

Novartis Investigative Site, Essen

999077

Novartis Investigative Site, Hong Kong

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

01307

Novartis Investigative Site, Dresden

104 0045

Novartis Investigative Site, Chuo Ku

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY